In separate 'warning letters' issued to Surat-based Amrutam Life Care and 14 other companies, the Food and Drug Administration (FDA) said they have been found to be selling illegal drugs labelled as medicines, dietary supplements and ayurvedic products for diabetes treatment.
Most of these companies have been selling 'India-originating' treatments for diabetes, while at least two of them have suppliers or associate companies in India, as per the letters.
FDA, which has been taking action against many Indian pharmaceutical companies for either deficiencies in their products or at manufacturing facilities, told Amrutam that there might be other violations as well in its products.
India is the second largest drug exporter to the US and Indian drugmakers have a significant presence there. Those having faced FDA action in recent times include Wockhardt, Fresenius Kabi, Ranbaxy, Sun Pharma, Cadilla, Aurobindo Pharma, RPG Life Science, Dabur and Glenmark.
Amrutam was selling products like 'Zoom-Zooma-Zoom', Arexi, Diexi and Obexi in the US in the online mode, but the FDA's laboratory tests found them to be "unapproved" drugs with undeclared ingredients.
You’ve reached your limit of 5 free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app